Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLES 14 AND 15 OF THE BELGIAN LAW
OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY
GHENT, Belgium, 8 March 2013 - Ablynx [Euronext Brussels: ABLX], the
biopharmaceutical company focused on the discovery and development of
Nanobodies®, announces today that the closing of its private placement
("Accelerated Bookbuild Offering"/"ABO") took place on 5 March 2013 and as a
result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares
were issued that same day as a result of the exercise of 641,800 warrants.
Ablynx NV also publishes the following information in accordance with article
15 of the Law of 2 May 2007 on the publication of major shareholdings in
issuers whose shares are admitted to trading on a regulated market (the
Total amount of the share capital: €90,653,858.30
Total number of securities carrying voting rights: 48,505,516
Total number of voting rights (denominator): 48,505,516
Ablynx NV has in total 3,904,145 outstanding warrants, of which 1,657,700
warrants give the holder the right to a total of 828,850 shares (two warrants
giving the right to subscribe to one share) and of which 2,246,445 warrants
give the holder the right to a total of 2,246,445 shares (one warrant giving
the right to subscribe to one share). The acceptance and issuing of 467,500
warrants (one warrant giving the right to subscribe to one share) is pending.
The total number of voting rights, which can be acquired as a result of the
exercise of the outstanding warrants, amounts to 3,075,295.
In addition, Ablynx NV announces, in accordance with article 14 of the Law of
2 May 2007 on the publication of major shareholdings in issuers whose shares
are admitted to trading on a regulated market (the "Transparency Law"), that
it has received the following transparency notifications between 28 February
and 7 March 2013.
Notifier(s) Number of voting Percentage of voting
Gimv NV, Adviesbeheer Gimv Life Sciences 5,825,939 12.01%
NV, Adviesbeheer Gimv Life Sciences 2004
NV and Biotech Fonds Vlaanderen NV^1
Sofinnova Partners SAS 4,675,587 9.63%
^1 Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv
Life Sciences 2004 NV. Gimv NV (2,463,320 voting rights), Adviesbeheer Gimv
Life Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV
(433,745 voting rights) and Biotech Fonds Vlaanderen NV (2,928,874 voting
rights) are acting in mutual agreement. The Flemish Region in Belgium is the
ultimate shareholder of Biotech Fonds Vlaanderen NV.
The full versions of the transparency notifications are available on the
website of Ablynx (www.ablynx.com - investor relations).
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at
clinical development stage. Ablynx has on-going research collaborations and
significant partnerships with major pharmaceutical companies including
Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is
headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
press release in pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Ablynx via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.